BioXcel Therapeutics Highlights Upcoming Major Milestones
October 10, 2019 08:00 ET
|
BioXcel Therapeutics, Inc.
Clinical results expected 1H 2020 from BXCL501 Phase 3 trial for acute treatment of agitation in Schizophrenia and Bipolar patients Data also expected from BXCL501 Phase 1b in 1H 2020 for acute...
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
September 26, 2019 09:11 ET
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the...
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
September 25, 2019 16:27 ET
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Sept. 25, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that...
BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices
September 18, 2019 08:00 ET
|
BioXcel Therapeutics, Inc.
Neuropsychiatric patients are vulnerable to multiple agitation episodes; Alzheimer’s dementia patients specifically require integrated patient management solutions Expands market potential of...
BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)
September 04, 2019 08:00 ET
|
BioXcel Therapeutics, Inc.
Expansion of clinical development for BXCL701 program planned in hematological malignancies, beyond solid tumors (Pancreatic and tNEPC) Confirmation and further extension of key findings in Nature...
BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501
August 20, 2019 08:00 ET
|
BioXcel Therapeutics, Inc.
Expands clinical development of BXCL501 program for treatment of alcohol and substance use disorders (“ASUD”), related to post-traumatic stress disorder (“PTSD”) and traumatic brain injury (“TBI”) ...
BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
August 06, 2019 07:30 ET
|
BioXcel Therapeutics, Inc.
BXCL501 met primary endpoint in agitated schizophrenia patients with clinically meaningful, rapid and durable reduction in PEC score maintained for 4 to 6 hours in its Phase 1b, randomized, double...
BioXcel Therapeutics to Present at the Canaccord Genuity 2019 Annual Growth Conference
July 31, 2019 08:00 ET
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., July 31, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present...
BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update
July 30, 2019 16:01 ET
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., July 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), today announced that the Company is scheduled to release its second quarter and half year 2019...
BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia
July 22, 2019 06:00 ET
|
BioXcel Therapeutics, Inc.
Statistically significant mean reduction in PEC score at two hours compared to placebo following a single dose of 180 mcg (p<0.0001), with rapid and durable reductions in PEC score maintained for 4...